Drugs / MANP
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04542681 Comparator | May 2018 → Dec 2022 | resistant hypertension | Mayo Clinic | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MANP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04542681 ↗ |
| Route | Subcutaneous | “Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg” NCT04542681 ↗ |